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Background: A large phase III placebo-controlled, randomized efficacy trial of an investigational 11-valent
pneumococcal conjugate vaccine against pneumonia in children less than 2 years of age was conducted in the
Philippines from July 2000 to December 2004. Clinical data from 12,194 children who were given either study
vaccine or placebo was collected from birth up to two years of age for the occurrence of radiologically proven
pneumonia as the primary endpoint, and for clinical pneumonia and invasive pneumococcal disease as the
secondary endpoints. Several tertiary endpoints were also explored. Along the core trial, several satellite studies on
herd immunity, cost-effectiveness of the study vaccine, acute otitis media, and wheezing were conducted.
Results: We describe here in detail how the relevant clinical records were managed and how quality control
procedures were implemented to ensure that valid data were obtained respectively for the core trial and for the
satellite studies. We discuss how the task was achieved, what the challenges were and what might have been done
differently.
Conclusions: There were several factors that made the task of data management doable and efficient. First, a pre-
trial data management system was available. Secondly, local committed statisticians, programmers and support staff
were available and partly familiar to clinical trials. Thirdly, the personnel had undergone training during trial and
grew with the task they were supposed to do. Thus the knowledge needed to develop and operate clinical data
system was fully transferred to local staff.
Trial registration: Current Controlled Trials ISRCTN62323832Background
Streptococcus pneumoniae causes high morbidity and
mortality from pneumonia and invasive disease among
young children particularly in low income countries [1].
Preventive measures, such as vaccination, are important
strategies for the control of pneumococcal disease [2]. A
phase III clinical trial was conducted in the Philippines
to evaluate the efficacy of an investigational 11-valent
pneumococcal conjugate vaccine (11PCV) against pneu-
monia in children less than two years of age [3]. The* Correspondence: leilanitn@yahoo.com
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international collaborators: the Research Institute for
Tropical Medicine (RITM), Philippines; the National In-
stitute for Health and Welfare (THL, formerly KTL), Fin-
land; the University of Queensland (UQ), Australia; the
University of Colorado (CU), USA, and the developer
and manufacturer of the 11PCV, Sanofi Pasteur, France.
During the trial, various operational challenges were
encountered by the investigators. These included the
trial infrastructure preparation and implementation
according to Good Clinical Practice requirements, com-
munication in the context of a multinational collabor-
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of a low income country. The trial protocol had one pri-
mary endpoint, which drove the sample size, as well as
several exploratory secondary, and tertiary objectives. In
addition, several satellite studies were nested in or con-
ducted alongside the core trial. These included a herd
immunity study, a nested immunogenicity and reacto-
genicity study, an epidemiologic disease burden study of
pneumonia, suspected meningitis and sepsis, a cost-
effectiveness study, and the studies on Acute Otitis
Media (AOM), wheezing and pertussis. All this taken to-
gether posed a considerable challenge to the way data
were managed in the trial.
The primary task of data management was to assure
that clinical endpoints detected at the hospital emer-
gency ward or during outpatient consultations were
events that were coming from children enrolled in the
trial (i.e. from the genuine trial subjects), and that the
vaccination status was determined correctly. Since the
trial included various records of the trial subjects (such
as baseline infancy data sheets, health record informa-
tion, vaccination records, etc.), issues of quality and reli-
ability of the data were also important aspects that had
to be monitored. Moreover, since the project was not
only concerned with trial data but other studies as well,
linkage of records across studies and implementation of
quality controls were also crucial to follow-up. The aim
of this article is to document the processes and lessons
learned from the data management of the various stud-
ies conducted in the Philippines under the ARIVAC
consortium.
Results
Study setting of the core trial
The core trial conducted on the Island of Bohol, central
Philippines (Figure 1) was a phase III individual rando-
mized double-blind, placebo controlled trial (RCT) of an
11PCV against pneumonia in children less than 2 years
of age (ISRCTN62323832). Enrolment of the trial sub-
jects was conducted from July 2000 to December 2003.
They were followed up until December 2004. The
detailed conduct and the main results of the trial have
been described previously by Lucero et al. [3]. In brief,
vaccination was administered in 48 barangay health sta-
tions (BHSs) in 6 municipalities in the province. The pri-
mary endpoint in the core trial was radiologically proven
pneumonia, diagnosed in one tertiary care 250-bed gov-
ernment hospital [i.e. admission and outpatient depart-
ments (OPD) of the Bohol Regional Hospital (BRH)],
and in three smaller 50-bed private hospitals.
Study population
In the trial cohort, children were divided into three
major study groups. The primary study group [i.e. theRCT group] comprised of those who were recruited and
enrolled in the efficacy trial of the 11PCV against pneu-
monia (N= 12,194). A subset of the RCT group of 1,111
children was enrolled into the nested immunogenicity
study according to their place of residence (three areas
were chosen for this; for further details see Ugpo et al.
[4]). The second study group [named EPI group] com-
prised of children who either refused or were excluded
from enrolment in the RCT (N= 577). This group were
collected routine vaccinations they availed from the
immunization program of the government. Their
hospitalization and consultation in the hospitals under
endpoint surveillance were also collected. The third
study group [named the EPI grey study group] com-
prised of children who had either pneumonia, suspected
meningitis, suspected sepsis, AOM or pertussis, and
who came for hospitalization or consultation in the hos-
pitals under endpoint surveillance but were not enrolled
in the RCT at the time of the event. These children had
either not been enrolled in the RCT at the time of the
hospitalization or consultation or were too old to qualify.
The children in the third study group did not have vac-
cination records in the database and only minimum
demographic information was collected at every contact
with the child (such as the name of the child, date of
birth, sex, address, name of mother and if he/she
received first Diphtheria-Tetanus-Pertussis (DTP) vac-
cination). Each hospitalization or consultation was con-
sidered to be independent and no attempt was made to
inter-link the records.
Satellite studies
Several additional satellite studies were conducted in
conjunction with the core trial (Table 1).
Herd immunity
Starting in January 2002, the field nurses recruited sub-
jects for the herd immunity study. There were 1,843
infants enrolled in the efficacy trial with elder sibling
who enrolled in the herd immunity study. The herd im-
munity study was conducted to assess the possible herd
immunity effects of the 11PCV (i.e. reduction of vaccine
type/group-specific carriage of Streptococcus pneumo-
niae in the population; www.pneumocarr.org). This
study assessed the effect on the siblings of the nasopha-
ryngeal pneumococcal carriage of a younger sibling who
had been vaccinated with the 11PCV. Nasopharyngeal
swabs for detection of pneumococcal carriage were col-
lected at the enrolment (6 weeks of age) and at the mea-
sles vaccination visits (9 months of age).
Cost effectiveness
The cost effectiveness study started in October 2001 and
details of hospitalization and consultation of those
Figure 1 The map of the trial area. The trial participants’s homes are marked with black dots. The geographic data was collected later, during
the years 2008-2009. In the insert, map of the Philippines showing Bohol and in the Bohol map the 6 municipalities included in the trial are
colored with yellow. Base map: http://www.openstreetmap.org/?lat=9.6708&lon=123.9147&zoom=12&layers=M.
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2004. There were a total of 1,499 hospitalizations and
consultations for pneumonia, suspected meningitis and/
or suspected sepsis that were included in the cost effect-
iveness study. The data collected were the length of
hospitalization, diagnostic tests, special services and pro-
cedures done, physician’s fee, pharmaceutical costs, oxy-
gen use and devices used during hospitalization and
consultation as well as parental loss of income.
Miscellaneous studies
Children in the RCT, EPI and EPI grey study groups
who remained in the trial area, were enrolled in a few
other studies (i.e. AOM, wheezing and pertussis studies,
respectively) until they reached the age of 5 years.
The AOM and wheezing studies started in February
2002 and children enrolled were diagnosed with pneu-
monia and/or AOM. The study subjects were less than
5 years old. The pertussis study started in July 2001 with
a study population that included children less than
13 years old. This study included older children (not ne-
cessary enrolled in the RCT) who qualified the criteria
for pertussis. Data for AOM, wheezing and pertussis
were collected until December 2004. In the AOM and
wheezing studies, 2,018 children with one or more thanepisodes of hospitalizations and consultations were en-
rolled. The AOM and wheezing studies aimed at deter-
mining the presence of AOM and wheezing in children
less than 5 years who were hospitalized at BRH or con-
sulted at BRH-OPD. The data collected included pres-
ence of cough, duration of cough, ear pain, irritability,
vomiting, methods of ear examination, diagnosis of ear
examination, laboratory samples collected and episodes
of wheezing. In the pertussis study, 219 children with
one or more than episodes of hospitalizations and con-
sultations were enrolled. The data collected included
duration of cough, presence of paroxysmal cough, vomit-
ing (induced by cough), whooping cough, and suspicion




All births occurring since February 2000 in the six study
municipalities were followed up for possible recruitment
in the core trial. Basic demographic information and the
intention of the parents/guardians to have their child
participate in the trial were collected. Information on
the place of residence and the first DTP vaccination
were obtained from the parents/guardians. This was
Table 1 Description of the study populations
Study Study areas Age of population Study group
Phase 3 RCT study
Efficacy study 6 study municipalities Children aged 6 weeks to 6 months
and monitored until 2 years old
RCT
Nested study 3 predefined health centres
included Dao (Tagbilaran),
Danao and main health
centre in Panglao
Children aged 6 weeks to 6 months
and monitored until 2 years old
RCT
Epidemiological study of pneumonia,
meningitis and sepsis
Hospitalization in BRH 6 study municipalities Children less than 5 years old RCT, EPI and Epi grey
Hospitalization in the private hospital
and OPD consultation in BRH
6 study municipalities Children less than 2 years old RCT, EPI and Epi grey
Satellite studies
Herd immunity 6 study municipalities Children enrolled in the efficacy
study w/elder sibling enrolled
in the efficacy study
RCT
Cost effectiveness(hospitalization for pneumonia, sepsis,
or meningitis at BRH and three private hospitals)
6 study municipalities Children enrolled in the efficacy
study from 6 weeks to 23 months
old and admitted to hospital or
consulted the OPD
RCT
Acute otitis media(hospitalization or consultation at
BRH for pneumonia, sepsis, or meningitis)
6 study municipalities Children less than 5 years old
diagnosed with pneumonia
and/or AOM
RCT, EPI and Epi grey
Wheezing(hospitalization or consultation at BRH for
pneumonia, sepsis, or meningitis)
6 study municipalities Children less than 5 years old RCT, EPI and Epi grey
Pertussis(hospitalization or consultation at BRH for
pneumonia, sepsis, or meningitis)
6 study municipalities Children less than 13 years old RCT, EPI and Epi grey,
children not necessary
enrolled in RCT
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she talked with the parents/guardians about the trial.
These activities were undertaken by the study nurses to
facilitate recruitment and to give time to the parents/
guardians to make decision before enrolment.
During the first vaccination visit, the study nurse or
study physician ascertained that the infant fulfilled all
the inclusion criteria, did not present with the exclusion
criteria, and that the parent/guardian signed the
informed consent form. The study nurse filled in an in-
fant data information sheet containing basic demo-
graphic data of the child and the mother, and assigned
unique child identification (Child_ID) number. Based on
the randomization list, which was produced by the
pharmaceutical partner of the trial, the nurse allocated
the child to either receive the study vaccine (11PCV) or
the saline placebo. The infant data information sheet
constituted the primary record of the child. During the
first visit, the study nurse also issued to the parent/
guardian a health card (commonly known as the “yellow
card”) with a Child_ID sticker pasted on the card. The
vaccinations received, among other information, were
recorded into this card. To identify the child’s enrolment
in the trial, the parent/guardian was requested to alwaysbring the child’s yellow card with them whenever the
child visited the health centre or hospital.
Vaccination
After enrolment, the child received the first dose of the
trial vaccine or placebo at the minimum of 6 weeks of
age. The second dose was scheduled to be given 4 weeks
after the first dose and the third dose 4 weeks after the
second dose. Administration of the study vaccine and
concomitant vaccines (BCG, OPV, DTP/PRP~T, HBV,
measles and vitamin A) were recorded on the vaccin-
ation case report form (CRF).
Those not enrolled in the trial received routine
Expanded Program of Immunization (EPI) vaccines
(BCG, OPV, DTP, HBV, measles and vitamin A) available
from the health centre supply. This data was collected
and recorded on a shorter version of the vaccination
CRF.
Before vaccination, the child was assessed for the pres-
ence of any permanent or temporary contraindications.
The study nurse had a list of questions to assist her in
assessing the eligibility of the child to receive the vaccin-
ation. The presence or absence of contraindications was
recorded on the contraindication CRF. If there was a
Sanvictores et al. BMC Research Notes 2012, 5:274 Page 5 of 11
http://www.biomedcentral.com/1756-0500/5/274temporary contraindication, the vaccination was post-
poned to the next scheduled health centre vaccination
visit (~4 weeks later). If there was an absolute contra-
indication, the child was excluded from the trial.
Hospitalization and consultation due to pneumonia
Hospitalizations due to pneumonia at BRH and the 3
private hospitals were monitored daily for children less
than 5 years. Consultations in the out-patient depart-
ment of the BRH (BRH-OPD) were monitored only on
working days. Each hospitalization and consultation of
the child was given a unique identification (chrono-
logical order) number. A child could have several hospi-
talizations during the trial. Hospitalization from BRH
was recorded using a different CRF, because besides
pneumonia, also initial diagnoses of meningitis and sep-
sis were recorded. For hospitalizations in the private
hospitals and the BRH-OPD only pneumonia cases were
recorded.
Any hospitalization in the BRH due to pneumonia in
children not enrolled in the core trial and aged 6 weeks
to 59 months was collected for the epidemiology study.
Also consultations of pneumonia in the BRH-OPD and
hospitalizations due to pneumonia in the 3 private hos-
pitals for children aged 6 weeks to 23 months were
included in the epidemiology study. Initial diagnoses of
meningitis and sepsis in the BRH were also included in
the epidemiology study.
Laboratory sample collection during hospitalization and
consultation
Several samples [blood, pleural fluid, nasopharyngeal
swabs and aspirate, urine and cerebrospinal fluid (CSF)]
for laboratory tests were collected during hospitalization
due to pneumonia, meningitis and/or sepsis in the BRH.
For OPD consultations nasopharyngeal aspirate was col-
lected using systematic sampling of every 5th patient.
These were recorded using a laboratory CRF and
indexed with the same hospitalization identification
number compared to the hospitalization or consultation.
Serious adverse events (SAEs)
An SAE was defined as any untoward medical occur-
rence after immunization that resulted in death, was life
threatening, required in-patient hospitalization or pro-
longed existing hospitalization, or resulted in persistent
or significant disability/incapacity. SAEs were monitored
in eight hospitals in the study area as well as in the 48
barangay health stations. Information on hospitalizations
of study infants from 6 weeks to two years of age
belonging to the RCT group was identified, followed up
and recorded by using a screening log form. During vac-
cination days, study nurses questioned barangay health
stations’ staff about any SAEs and deaths in the area.SAEs were reported to the safety monitoring team of
local and Finnish physicians who will review and classify
the SAE for periodic or immediate reporting to the vac-
cine manufacturer, Sanofi Pasteur. Periodically reported
SAEs are reported monthly while immediately reported
SAEs are reported within 48 h from the time the event
become known to the investigators.
Clinical data management system (CDMS)
Description of the CDMS
Data collection and information system requirements
originated from the need of regular, effective and timely
monitoring and reporting during the trial. This was also
essential for the statistical analyses once the trial was
completed. The primary goal of the clinical data man-
agement system (CDMS) was to allow these reporting
requirements to be met, while ensuring the integrity and
validity of the data being collected. It was necessary that
multiple users were simultaneously able to make modifi-
cations to the data and to generate reports from real
time data in the database [5]. A decision was made to
recommend a specific data management system instead
of purchasing a commercial CDMS [6].
The scope of the CDMS was defined by the “data dic-
tionaries” (DDs; in total 57 for all studies) containing
metadata of CRFs and by other general reporting or in-
formational requirements. The DDs contained descrip-
tion of forms and other information sources of each
study and contained short description of the data: vari-
able names, short explanation, code lists, legal values,
format and length. The DDs were maintained by the
data manager (DMG) and were defined in conjunction
with the trial investigators. The DDs were created along-
side the paper forms, such as CRFs. The CRFs were used
to initially collect the data by trained nurses, technicians
and doctors before entry into the CDMS. To facilitate
entry, the data entry screens were one-to-one matches
for the paper forms (i.e. the data entry screen looked
similar to the paper format). The database structure,
tables and definitions of fields were developed from
DDs. The database was not normalized (i.e. more like
wide form in statistics datasets) [7] and the tables were
almost one-to-one with paper forms. The number of
tables in the database was over 60 including code lists
and the total number of fields in the database reached
2,300.
A provisional database had to be implemented in the
start of the core trial, because the data management sys-
tem contracted from a third party (systems developer in
Australia) was not yet complete and in order to report
in time the progress of the trial. The provisional data-
base was used only for 2 months and the final version of
the Microsoft SQL server database was installed in
Bohol Data Centre (BDC) in October 2000. Data entered
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final database due to the differences in the system and
definitions.
Reporting was accomplished by exporting the rele-
vant data tables from the Microsoft SQL Server data-
base to a Microsoft Access database, which were then
transformed and used by SAS scripts to generate reports
in HTML format. The reports were generated monthly
and delivered to the relevant members of the trial
consortium for monitoring, informational purposes and
other requirements.System overview
The Relational Database Management System (RDMS)
consisted of Microsoft SQL Server 7 and a Visual Basic
6 front end combined with various Microsoft Access
2000 client fields. The operating system was Windows
NT Server 4.0 for the database server and Windows NT
4 Workstation for the clients.
There was also an application for checking the edits,
which was created using Microsoft Access 2000. This
application contained miscellaneous reporting tools,
such as the “Vaccination Schedules” generator. Most im-
portantly, it contained a module for double entry valid-
ation that was for checking of discrepancies between the
first and second entry data.
To keep track of changes in the database and to re-
strict privileges, each user had an account and changes
were audited with the track including the following in-
formation: the site where the data was created, the date
when the record was created, the person who modified
the record and the date of modification.Personnel
The BDC was composed of a senior data manager, as-
sistant data managers, system administrator, and data
entry persons. In general, the staff performed often more
than just a one major function. For example the data
managers also performed SAS programming and data
analyses. This was deemed advantageous because know-
ledge of the different studies and in-depth understanding
of contents, history, restrictions and the relationships of
the data were necessary to perform these functions. The
trial had a high retention of its personnel due to good
working conditions and training provided. Hiring of add-
itional personnel was necessary during the peak period
of the data entry.
The personnel were continuously trained to use the
CDMS, to handle data management tasks, to do SAS
programming and to administrate the database system.
Close monitoring of the UQ counterpart was necessary
to maintain the high performance of the data manage-
ment unit.Supervision
The BDC was under the direct supervision of the UQ
and the RITM. The BDC data manager liaised with the
international and local consultants. Quarterly visits in
the BDC were conducted by the UQ personnel to moni-
tor the activities, to directly train personnel and eventu-
ally to transfer the responsibility of managing the data
and maintaining the database system. The RITM investi-
gators conducted monthly visits in the BDC to monitor
the activities and to resolve any administrative issues. In
the middle of 2003, most of the trial data management
was handled by the BDC. The UQ remained as a con-
sultant and was regularly updated on the activities at the
study site.Quality control
Management of CRF
The CRFs were in triplicate paper copies, which served
as the backup copies for the consortium members
(Table 2). After the CRFs were filled, the supervisor
reviewed the forms before they were submitted for the
data entry at the BDC. For the practical reasons and
clarity, the first copy was used as a reference for the data
entry. After the data entry, the first copy was stored in a
different building to ensure that backup copy was safe.
Submission of vaccination CRFs was done by the
centre visits per child rather than separately by forms.
For the hospitalizations, submission of CRF was also per
hospitalization and included laboratory and bacteriology
CRFs, if required. Usually a certain schedule was fol-
lowed with the submissions of the CRFs to give time for
data entry, cleaning and validation before the production
of monthly reports.Data entry
All CRFs from the different studies (of the children en-
rolled in the core trial) were entered twice by two inde-
pendent data entry officers. For the remaining subjects,
any CRFs arising from participation in any of the other
studies were single-entered in the database. The birth
and death records, which were collected from the public
documents (e.g. the church, civil register, hospital and
health centre records) were single-entered. The data
entry contained integrity checks, range checks and busi-
ness rules of the trial.
The core data were stored in the database server in
two separate databases: the first entry and the second
entry database. This process enabled separate entries,
since the data entry was not dependent on whether the
data were already entered in the primary database
(which was the first entry for this study). For the
remaining subjects, all data were entered in the primary
database only.
Table 2 Case report form (CRF) types submitted per child
Event CRF
First vaccination visit Birth event report
Infant data sheet
Vaccination CRF
Herd immunity (if applicable)
Second vaccination visit Vaccination CRF
Third vaccination visit Vaccination CRF
Measles vaccination visit Measles CRF
Herd immunity (if applicable)
Postponement visit Postponement CRF







Hospitalization in private hospitals Hospitalization CRF
Radiology
Cost effectiveness







Completion/Termination visit Completion CRF
Any sae Serious Adverse Event Report
Death Death event report
Verbal autopsy (if applicable)
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sessment was made about the continuation of double
data entry in light of the very minor errors. The conclu-
sions of the assessment were that it took six to seven
months for error rates to stabilize and that there was
considerable variation by the type of CRF. Particularly
there were high error rates in the Infant Data Sheet, Ser-
ious Adverse Event and Admission CRFs. The results
were presented to the Data Safety and Monitoring Board
(DSMB) in July 2001 [8]. It was decided by the consor-
tium to retain double data entry as one of quality mea-
sures implemented on the data. Double data entry was
suggested to ensure and reassure that data on the CRFs
were correctly transcribed into electronic format,
monthly error rates of child data are shown in Figure 2.Validation and cleaning of the data
The data validation method was done stepwise during
entry, periodically in the database and with separate
logic in SAS depending on the nature of errors traced
[9]. The validation was done on the entire database of
both entries from the very beginning of the study to the
most current data. The first stage of validation com-
pared the first and second entries for the data that were
double-entered. The data was transformed to SAS for-
mat for validation and data validation procedures were
written in SAS language using the comparison proced-
ure to compare the two entries. Comparison was made
variable by variable in each table in the databases and a
report was generated indicating the variable and its value
that did not match within the databases. Since compari-
son was done on the entire database, any correction or
updates on the data definition were implemented on the
entire database. Audit trails were produced to document
data entry and correction. Once both entries had been
exactly matched, the first entry (which included all data
of both enrolled and not enrolled children) was used to
perform data analysis. Series of validation procedures
were developed and performed in validation of CRFs,
range checks, inconsistencies, and univariate and multi-
variate checks. This was an addition to the CDMS integ-
rity, checks which were concurrently applied during data
entry (Figure 3). Validations were run on the entire data-
base monthly. These validations were regularly reviewed
and updated by investigators who were experts in a par-
ticular CRF or study and by the data managers who had
in-depth knowledge of the database.
On-site and monthly validation and cleaning of the
database contributed advantageously to the project, be-
cause the volume of CRFs to be corrected was manage-
able for the data managers, and for the field and hospital
personnel who collected the data. It was also easier for
the field and hospital personnel to recall the recent data
or go back to the source, when required. An independ-
ent data monitoring team (IDMT) which was formulated
on the recommendation of the DSMB randomly checked
a certain percentage of case report forms monthly.
Correction of the CRF entries
Corrections of the CRF entries were performed directly
on the paper CRF following a standard operating proced-
ure (SOP). In order to keep tract of any corrections and
movement of the CRF, a query sheet was designed to rec-
ord this information. The query sheet was attached to
the CRF and issued by the data manager. The query sheet
was a preformatted form and filled-in with information
on the data to be corrected, reason for its error, name of
the CRF and name of the study nurse who completed the
CRF. The query sheet was given to the personnel who
made the correction. The information on the query sheet
Figure 2 The monthly error rates in Numeric Fields of the “Child Data” in the First 12 Months of Double Data Entry.
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to evaluate the performance of the study nurses.
There were 4,508 data queries that were issued from
December 2000 to February 2005. The most common
errors were wrong entries. Other errors were inconsist-
ent entries within the form and/or compared to other
forms. Quality assurance on the filling of the BDC cop-
ies of the CRFs was performed on a quarterly basis. Ten
percent of the forms filed at the BDC office were manu-
ally checked by the data managers for completeness and
consistency.
Reporting
Monthly trial progress summary and monthly total num-
bers of birth, recruitment, vaccination, SAE, pneumonia
admission and consultation, completion and termination
were reported. Other reports produced were quarterly
summaries of the data safety monitoring board (DSMB)







Figure 3 An example of the integrity checks inherent in the databasereports were sent out to the consortium via email in a
secure encrypted form. Later on, when the ARIVAC
website was constructed, the reports were posted in the
secure area.
Code breaking
When analysing the data, sessions of code breaking are
organized to maintain and keep the trial vaccine/placebo
codes blinded. The goal of blinded analysis is to ensure
that any person involved in developing analyses is not at
any stage exposed to the true values of the trial vaccine/
placebo codes. The 11PCV/placebo was randomized
using letter codes from A to F (3 letters for 11PCV and
placebo). The vaccines bearing these letter codes were
allocated to the children according to a scratchable
randomization list provided by Sanofi Pasteur.
Analysis scripts were developed using the scrambled
version of the Master database, where the key variable of
11PCV/placebo was replaced with randomly allocatedIntegrity check
tion number Duplication of child_id
y number Duplication of hospital number
tion number Check child_id exist in IDS
perature Range check
me If seriousness=death then outcome
should be death.
system.
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were run over the complete data with real 11PCV/pla-
cebo codes. A third person external to the project was
hired to make this codebreak and ensure that the data
remained blinded.
This person opened and used the 11PCV/placebo
codes to run the analysis, and ensured that the 11PCV/
placebo codes were secured after the analysis was
complete. Outputs from the unblinded analysis were dis-
tributed to the ARIVAC consortium. To protect the in-
tegrity of the primary objective of the trial, the
manuscript on the primary results was first published
before unblinded data were given to researchers.
Discussion
Clinical data management of this 11PCV efficacy trial
and related satellite studies was challenging, because of
the magnitude of data collection and the corresponding
complexities presented by the simultaneously conducted
studies. One of the challenging tasks was to keep track
of children with multiple clinical events, i.e. all the dif-
ferent outcomes studied. These multiple clinical events
and all information from the different studies had to be
linked accurately. It was laborious to maintain the qual-
ity of the data, and the linkage of various clinical data
records to establish relationships. However, due to care-
ful trial preparation and conscious efforts to follow SOPs
for data collection and management, the data manage-
ment team cleaned, corrected and properly joined data
from various sources.
Despite all the trial preparation activities, the approach
taken during the initial design of the data entry applica-
tion did not take into account that major changes would
need to be implemented in the CDMS during the course
of the trial. The data management group attempted to
reduce the effort necessary to implement new modules
in the system, and these efforts, combined with the ori-
ginal design, formed the final architecture.
Given the extensive data entry validation requirements,
the approach taken with low level of database normalisa-
tion and the database design was, initially, to leave
validation-related code in separate application. This
greatly simplified the database design and coding. Report-
ing was done with external system in SAS using data
exported from database. This made data entry and data-
base design less dependent from reporting. It could have
been possible to follow all standard database design tech-
niques instead of using straight forward copies of paper
forms in database design; this design complicated imple-
menting changes in database. This is a question about
which tools the personnel is already familiar with and how
much already existing code can be reused. For some insti-
tutions in the ARIVAC consortium SAS as a major statis-
tics programming environment was a natural choice formany tasks in data validation and reporting. Problems
arose in meeting deadlines for the verbatim report for the
SAE prepared by the local safety monitoring team. Lack of
coordination among the data managers and the manual
computation of the figures to be included in the report
were some of the causes for the delay.
The trial recruited local statisticians who learned how
to manipulate data management and statistical software
through regular trainings provided by the UQ data man-
agement experts. Although the CDMS evolved, the lo-
cally hired data management team became skilled in
operating the system. There was considerable turnover
in the data management team, but new staff quickly and
efficiently gained knowledge of the system after training
sessions conducted by the UQ.
Data collection officially ended December 2004. Some
field trial staff, i.e. study nurses and physicians remained
until end of 2005 to answer questions arising from the
data processing. Data management team personnel, par-
ticularly the statisticians, were still available part time
until 2009, when the main trial results were published
[3]. An additional study of the geographic locations of
children’s homes and services in the study area took
place in years 2008–2009 with core members of the data
management team [10]. Because of the skills that had
been acquired, the local data management team was able
to apply to this and other new research projects that had
hired them. This was a great benefit to the research
community at the RITM, in Manila. Continuation of
data management is also important for the future use of
the data for research and personnel familiar with the
data solves queries of the researchers fast and reliably.
At the time of this trial, the data collection in the
developing country settings had to rely on paper CRFs
and recent development towards Electronic Data Cap-
ture (EDC) and/or web based distributed data collection
and management was not considered [11]. At the time
of the trial, the BHS had neither computer systems nor
advanced telecommunications systems to support dis-
tributed data collection. Therefore, data collection and
queries for quality control had to rely on paper forms,
phone calls and fax [12].
We have hereby shown that in this complex, rando-
mized, controlled trial to determine the efficacy of an in-
vestigational pneumococcal conjugate vaccine against
childhood pneumonia (conducted in a developing coun-
try setting and involving concurrent satellite studies)
data management needs/requirements were successfully
met. There were several factors that made the task of
data management doable and efficient. First, a pre-trial
data management system established during the prepara-
tory hospital based and immunogenicity studies in the
population to obtain important background information
about pneumonia, gave the trial a head start to conduct
Table 3 Summary table of key learnings
Do’s Don’ts
To function effectively and efficiently,
careful trial preparation and conscious




of responsibilities and operational
leadership in such distributed
project
The international collaboration
of data management personnel
from the Philippines, Australia,
and Finland managed to work
effectively through different
means of communication
The vaccine did not go further
in licensure path – manufacturer
withdraw and thus rest of
consortium took response of
management – reorganizational
difficulties
Having committed and trained
data management personnel is
one of the significant factors in
the conduct and success of a
large clinical trial
Allocation of resources for post
processing of data – timetable
was stretched
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resources like statisticians, programmers and support
staff were recruited to help in data collection and man-
agement. Thirdly, the personnel had undergone training
by experienced senior statisticians and programmers.
Moreover, updating training was conducted locally and
internationally throughout the study period. Fourthly,
there was a health care data infrastructure utilizing the
English language in the health records, which contribu-
ted to the ease of clinical data collection in this inter-
national project. Finally, a centralized data entry system
combined with a semi-automated quality control
resulted in a fairly fast feedback of corrections and high
quality data with low error rates.
Although data management was successfully conducted,
some problems arise during the trial. Trusting the func-
tionality and reliability of the data management system
building up the final database for data analyses, a full-time
statistical expert from Australian collaborators was not
hired for the entire duration of the trial to supervise the
local data analyses [13]. We therefore encountered pro-
blems inherent to long-distance communication with the
international statistical experts. Also the distributed ad-
ministrative responsibilities of the consortium and unclear
roles in new situations sometimes delayed decision mak-
ing. Since the vaccine was an investigational product
which was dropped from further licensure pathway, pro-
ducer withdraw from the project and did not support post
project data management or analysis. The need for human
resources for post processing and analysis was underesti-
mated. All this resulted in a one-year delay in providing
the first results of the trial (Table 3).
Conclusions
International research in developing country with many
counterparts is challenging. To be successful one needs to
deliver resources correctly to different places, to differenttasks and on right time. It is important to find out what
kind of resources, especially different professionals are
available and where. This demand can be fulfilled by train-
ing new professionals, hiring existing ones or outsourcing
services. Language and cultural barriers needs to be
crossed to make such a large project working. In this case
we did all these things keeping in mind sustainable cap-
acity building in local institutions in the Philippines.
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